Literature DB >> 15128776

Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand.

Joaquín Madrenas1, Luan A Chau, Wendy A Teft, Paul W Wu, Jason Jussif, Marion Kasaian, Beatriz M Carreno, Vincent Ling.   

Abstract

Abs or their recombinant fragments against surface receptors of the Ig superfamily can induce or block the receptors' native function depending on whether they induce or prevent the assembly of signalosomes on their cytoplasmic tails. In this study, we introduce a novel paradigm based on the observation that a bispecific tandem single-chain variable region fragment ligand of CTLA-4 by itself converts this inhibitory receptor into an activating receptor for primary human T lymphocytes. This reversal of function results from increased recruitment of the serine/threonine phosphatase 2A to the cytoplasmic tail of CTLA-4, consistent with a role of this phosphatase in the regulation of CTLA-4 function, and assembly of a distinct signalosome that activates an lck-dependent signaling cascade and induces IL-2 production. Our data demonstrate that the cytoplasmic domain of CTLA-4 has an inherent plasticity for signaling that can be exploited therapeutically with recombinant ligands for this receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128776     DOI: 10.4049/jimmunol.172.10.5948

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

2.  A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity.

Authors:  Wenlong Tan; Yanchun Meng; Hui Li; Yang Chen; Siqi Han; Jing Zeng; Ang Huang; Bohua Li; Yanyun Zhang; Yajun Guo
Journal:  MAbs       Date:  2013 Nov-Dec       Impact factor: 5.857

3.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Authors:  Andreas Herrmann; Saul J Priceman; Piotr Swiderski; Maciej Kujawski; Hong Xin; Gregory A Cherryholmes; Wang Zhang; Chunyan Zhang; Christoph Lahtz; Claudia Kowolik; Steve J Forman; Marcin Kortylewski; Hua Yu
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

4.  Intracellular concentrations of Ca(2+) modulate the strength of signal and alter the outcomes of cytotoxic T-lymphocyte antigen-4 (CD152)-CD80/CD86 interactions in CD4(+) T lymphocytes.

Authors:  Asma Ahmed; Sambuddho Mukherjee; Dipankar Nandi
Journal:  Immunology       Date:  2008-08-14       Impact factor: 7.397

Review 5.  Biology drives the discovery of bispecific antibodies as innovative therapeutics.

Authors:  Siwei Nie; Zhuozhi Wang; Maria Moscoso-Castro; Paul D'Souza; Can Lei; Jianqing Xu; Jijie Gu
Journal:  Antib Ther       Date:  2020-02-17

Review 6.  Current progress in innovative engineered antibodies.

Authors:  William R Strohl
Journal:  Protein Cell       Date:  2017-08-18       Impact factor: 14.870

7.  Structure-Function analysis of the CTLA-4 interaction with PP2A.

Authors:  Wendy A Teft; Thu A Chau; Joaquín Madrenas
Journal:  BMC Immunol       Date:  2009-04-30       Impact factor: 3.615

8.  Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.

Authors:  Li-Te Chin; Chishih Chu; Han-Min Chen; Shu-Ching Hsu; Bor-Chun Weng; Chi-Hong Chu
Journal:  BMC Biotechnol       Date:  2007-08-23       Impact factor: 2.563

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.